Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
← catalyst calendarNCT06609239 · readout in 1,615 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
900estimated
Sites
127
Countries
Argentina, Brazil, Canada +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-30 | actual | When the study began enrolling |
| Primary completion | 2031-01-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-01-20 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Intervention
- Drug: Lunsekimig — also filed as SAR443765
Primary outcome
what the primary-completion date above is the date OFExposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
measured From study baseline to week 148
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed